$DHR

Generating a unique summary for DHR…

AI-generated for information only — not investment advice.

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

Institutions hold 84.12% · insiders 10.81% · 2,887 institutions

Consensus score 1.46 (1 = strong buy, 5 = sell) · mean target 259.19

• CitigroupBuymain2026-10-22
• BarclaysOverweightmain2026-10-22
• JP MorganOverweightmain2026-10-22
• TD CowenBuymain2026-10-22
• StifelBuymain2026-10-22
• BairdOutperformmain2026-10-22
• Morgan StanleyOverweightmain2026-10-13
• TD CowenBuymain2026-10-13
• BarclaysOverweightmain2026-10-07
• RBC CapitalOutperformmain2026-10-05

Next report: 2026-10-21

• 8-KCorporate Changes & Voting Matters2026-10-21Open
• 8-KCorporate Changes & Voting Matters2026-10-13Open
• 25-NSENotification filed by national security exchange to report the removal from listing and registration of matured2026-09-30Open
• 8-KCorporate Changes & Voting Matters2026-08-03Open
• 8-KCorporate Changes & Voting Matters2026-07-21Open
• 11-KAnnual report of employee stock purchase2026-06-16Open
• S-8Offering Registrations2026-06-09Open
• 8-KCorporate Changes & Voting Matters2026-06-03Open
• SDSpecialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)2026-05-12Open
• 8-KCorporate Changes & Voting Matters2026-05-07Open

• What Does Danaher (DHR) FDA Clearance For AI AFib Detection Mean Now?

  Danaher (NYSE:DHR) subsidiary Masimo received FDA clearance for AI-enabled atrial fibrillation detection in its Radius VSM wearable monitor. The approved system uses artificial intelligence to identify potential AFib episodes in patients using Masimo’s hospital-grade wireless device. The AFib detection feature is intended for use in acute care settings, adding a new digital monitoring function to Danaher’s diagnostics tools. Masimo’s new AI atrial fibrillation clearance matters, but...

  Thu, 22 Oct 2026 20:13:36 +0000

• LH vs. DHR: Which Stock Is the Better Value Option?

  LH vs. DHR: Which Stock Is the Better Value Option?

  Thu, 22 Oct 2026 14:40:02 +0000

• Danaher (DHR) Q3 Earnings Fuel Stock Gains On Margin Expansion

  Danaher came into this Q3 2026 report with the stock already grinding higher over the past three months. It then jumped another 4.3% to about $233.86 after the release. The move looks like a relief rally, yet the core story sits in the income statement. Management delivered roughly $6.6b of revenue and pushed adjusted operating margin to about 29%, while earnings per share over the trailing year reached just above $6. That combination of higher profitability and solid earnings power is what...

  Thu, 22 Oct 2026 12:13:22 +0000

• DHR Q3 deep dive: execution focus and AI strategy underpin improved outlook

  Diversified science and technology company Danaher (NYSE:DHR) met Wall Street’s revenue expectations in Q3 2026, with sales up 8.3% year on year to $6.55 billion. Its non-GAAP profit of $2.11 per share was 10% above analysts’ consensus estimates.

  Thu, 22 Oct 2026 08:14:27 +0000

• Danaher (DHR) Stock Fair Value Edges Higher After Analysts Lift Targets

  Danaher is back in focus as analysts edge price targets into the US$240 to US$255 range, with some models now centering around fair value of about US$244.14. This shift reflects recent research that is divided between optimism on improving demand in life science tools and diagnostics, and concern that current valuations may already factor in a recovery, especially around bioprocessing. In the sections that follow, you will see how these updated targets fit into the broader narrative and what...

  Thu, 22 Oct 2026 04:26:04 +0000

• Why Danaher Stock Bounced Higher Today

  The conglomerate posted its latest set of quarterly earnings that morning.

  Wed, 21 Oct 2026 21:26:22 +0000

• Medical Giants Thermo Fisher, Danaher Reverse Higher — What Investors Are Seeing

  Thermo Fisher and Danaher stocks reversed higher Wednesday after reporting third-quarter metrics and full-year guidance.

  Wed, 21 Oct 2026 20:04:11 +0000

• Danaher: 3 Key Takeaways for Long-Term Investors

  Portfolio reshaping complete, management now pivots to organic growth and disciplined acquisitions to compound returns.

  Wed, 21 Oct 2026 18:40:28 +0000